Shandong Sinobioway Biomedicine (002581.SZ): The net income in the first three quarters was 14.6263 million yuan, a year-on-year decrease of 50.78%.

Gelonghui Finance · Oct 29 20:27

Glory Run on October 29丨Shandong Sinobioway Biomedicine (002581.SZ) announced its third quarter report for 2024, with the company achieving revenue of 0.315 billion yuan in the first three quarters, a 6.99% year-on-year decrease; net income attributable to shareholders of the listed company was 14.6263 million yuan, a 50.78% year-on-year decrease; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 16.5706 million yuan, a 49.02% year-on-year decrease; and basic earnings per share was 0.0222 yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

未名医药(002581.SZ)：前三季度净利润1462.63万元 同比下降50.78%

Shandong Sinobioway Biomedicine (002581.SZ): The net income in the first three quarters was 14.6263 million yuan, a year-on-year decrease of 50.78%.

Risk Disclaimer

Statement

未名医药(002581.SZ)：前三季度净利润1462.63万元同比下降50.78%